Clinical Trials
13 trialsNCT06130826 2026-06-03
Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer
City of Hope Medical Center
Phase 1 Suspended
NCT05063565 2026-06-01
ROWAN
Boston Scientific Corporation
Phase 2 Active not recruiting
NCT07162506 2026-05-29
DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR/PR After nCI
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT07594340 2026-05-22
HAIC vs. TACE Combined With Sintilimab and Bevacizumab for Intermediate HCC (Beyond Up-To-Seven)
Sun Yat-sen University
Phase 3 Recruiting
NCT07596290 2026-05-22
RADICAL
Beijing Friendship Hospital
Phase 2/3 Not yet recruiting
NCT07602140 2026-05-22
TACE Combined With Thermal Ablation and ADC, PD-1, and Chemotherapy as First-line Treatment for HER2-highly-expressing Gastric Cancer With Liver Metastases: A Multicenter, Single-arm Prospective Clinical Study.
Shandong Provincial Hospital
Phase 2 Not yet recruiting
NCT07595172 2026-05-19
NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer
West China Hospital
Phase 1/2 Recruiting
NCT07062055 2026-05-08
BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + SBRT for BCLC-C HCC With PVTT and/or Oligometastases
Shandong Cancer Hospital and Institute
Phase 2 Recruiting
NCT07000253 2026-05-07
OMEC-5
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 2/3 Recruiting
NCT06356584 2026-04-28
Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases
Shandong Cancer Hospital and Institute
Phase 2 Recruiting
NCT06974110 2026-04-15
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
Phase 1 Recruiting
NCT06960889 2026-04-14
A Retrospective Clinical Study Exploring Prognostic Factors in Esophageal Cancer Patients
Nanfang Hospital, Southern Medical University
Active not recruiting
NCT07522411 2026-04-13
Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma
Tongji Hospital
Phase 1/2 Not yet recruiting